The company has also added a group of industry experts to its advisory board.
Douglas most recently led Bridge4Bio, a business consultancy. Prior to this he was managing director and president of Hoefer, a division of Harvard Bioscience.
The new members of the advisory board are Lori Kunkel, who has held various senior positions in the industry, including chief medical officer at Proteolix/Onyx Pharmaceuticals and vice president of clinical development at Xenocor, and Paul Nowak, ceo of Biotix Holdings.
Nowak has spent the majority of his career at VWR International, a global distributor of laboratory supplies, where he held many positions, including ceo and president.
BioCision appoints coo
Also expands corporate advisory board
You may also like
Manufacturing
![Precise dosing valve developed for demanding laboratory and analytical systems]()
Precise dosing valve developed for demanding laboratory and analytical systems
Flow control specialist Bürkert has announced the release of a new dosing valve with media separation that offers minimal internal volume, fast switching times and high repeatability to ensure stable processes and reproducible results
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
Manufacturing
![How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing]()
How intelligent checkweighers offer improved productivity in pharmaceutical manufacturing
Precise weighing, automated reporting and tailored handling help pharmaceutical producers reduce waste, streamline compliance processes and maintain reliable output across demanding production lines
Manufacturing
![Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India]()
Shilpa CDMO invests $50m to expand peptide manufacturing capacity in India
The CDMO is investing $50m in additional solid-phase peptide synthesis capacity and a new commercial manufacturing line at its Raichur campus, expanding its capabilities to meet demand for GLP-1s and increasingly complex peptide therapeutics across oncology and rare diseases
You need to be a subscriber to read this article.
Click here to find out more.
Click here to find out more.
